Lakewood-Amedex Biotherapeutics Says It Obtained IRB Approvals, Site Readiness To Begin Phase 2a Trial Of Nu-3 In Infected Diabetic Foot Ulcers

Loading news article.

Lakewood-Amedex Biotherapeutics Says It Obtained IRB Approvals, Site Readiness To Begin Phase 2a Trial Of Nu-3 In Infected Diabetic Foot Ulcers | WAPE

Lakewood-Amedex Biotherapeutics Says It Obtained IRB Approvals, Site Readiness To Begin Phase 2a Trial Of Nu-3 In Infected Diabetic Foot Ulcers

Article summary

Related companies

Analyzed by WAPE AI.

Comments —